Direct renin inhibitor adjunct not helpful in T2DM patients at high risk for CV, renal events

November 16, 2012

Adding aliskiren to standard therapy with renin-angiotensin system blockade could be harmful and did not lower the risk of cardiovascular and renal adverse events when used in patients with type 2 diabetes at risk for these events, according to an online study in the New England Journal of Medicine.